Cadrenal Therapeutics Accounts Payable

Cadrenal Therapeutics (CVKD) currently reports a accounts payable of $870K as of June 2026. That compares with $900K in the prior-year period — down 2.6% year over year. Use the charts on this page to explore Cadrenal Therapeutics's accounts payable history and peer comparisons.

Cadrenal Therapeutics's accounts payable decreased from $900K to $870K — a 2.6% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cadrenal Therapeutics reported $870K in accounts payable as of June 2026. That compares with $900K in the prior-year period — down 2.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $870K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Cadrenal Therapeutics, and consider following CVKD for alerts when major investors trade the stock.